Company Research
Whether you are exploring new sales opportunities or researching a new investment, FirstRain provides unique insight into important developments for Allergan, Inc. (AGN). You can receive reports or configure the research engine for yourself.
Report On:
Allergan, Inc. (AGN)
HEALTHCARE - Drugs - Drug Manufacturers - Other
Generated: Thursday September 15, 2011 04:03 AM
|
|
||||||||||||||||||
Quotes About Allergan, Inc.
-
Banking on Botox no concern for Allergan CEO
It's just a question of when do we cruise past the $2 billion mark,"
- David Pyott -
Allergan steps up Latisse testing for baldness
If it works on male and female baldness, that's a big deal,"
- David Pyott -
Botox Maker Allergan Gets a Lift From Asia
Most of this started in South Korea, which is the Garden of Eden of cosmetic treatments,"
- David Pyott -
Allergan finds Asian market for Botox
It's like the difference between a Chrysler and a BMW,"
- David Pyott -
US sales of Botox continue to increase
During the recession, I used to say that for ladies, the face is the one outfit you wear every day,"
- David Pyott
No Comment
-
NTT DoCoMo, Allergan, Microsoft, Apple: Intellectual Property
Nam and Takashi Takebayashi, an Apple spokesman in Japan's capital, both declined to comment on the suit.
- Takashi Takebayashi
Latest Company Intelligence
-
Banking on Botox no concern for Allergan CEO
The Huffington Post | Sep 14,'11
NEW YORK (Reuters) - Allergan Inc <AGN.N> is not worried about over-reliance on sales of its flagship Botox drug, the company's chief said, citing extensive safety data and supply reserves of the injectable medicine. The wrinkle-smoothing treatment recently won U.S. approval to treat migraine headaches and overactive bladders, positioning it for an even bigger chunk of Allergan's sales -
Obesity Treatment Device Market Outlook
Advanced Medical Technologies | Sep 13,'11
The market for obesity devices in the U.S. is currently dominated by restrictive devices, including primarily adjustible gastric banding (e.g., Allergan's Lap-Band) but also Ethicon Endo-Surgery, Helioscopie, AMI GmbH, Bariatric Solutions GmbH, Cousin Biotech and others. The future market for these products will also be largely represented by restrictive devices, but in the period from -
Botox-Maker Allergan Tests Eyelash Lengthener for Baldness
Bloomberg.com | Sep 12,'11
Allergan Inc. has moved its eyelash treatment into the second clinical stage of testing as a therapy for baldness and expects to see data by the middle of next year, Chief Executive Officer David Pyott said. The product, Latisse, was approved in 2008 to aid in eyelash growth, and generated $82 million last year for the Irvine, California-based company. -
UPDATE 1-Court rules in Allergan's favor on Lumigan patent
Reuters UK | Sep 9,'11
Allergan Inc's ( AGN.N ) patent on its Lumigan drug is valid and was infringed by generic versions of the glaucoma treatment from Teva Pharmaceutical Industries Inc ( TEVA.TA ) and Sandoz Inc, a federal judge ruled. -
O.C. docs receive cash from drug makers
OC Watchdog - The Orange County Register | Sep 8,'11
ProPublica, the nonprofit news organization, has updated a searchable database of payments made by some pharmaceutical companies to doctors for speaking fees, meals and travel. Twelve drug companies now disclose their compensation to doctors and other health care workers, ranging from meals and travel to speaker fees. Allergan of Irvine discloses payments but only in a range. Most -
Lap-Band Deaths Pile Up As Sales Decline
Placebo Effect - BNET | Sep 8,'11
Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. You don't need a crystal ball to see that Allergan (AGN) has run into trouble on its Lap-Band stomach synching device: Its obesity intervention revenues sank 12 percent to %54.4 million in
FirstRain customers use intelligent business search to find actionable insights about companies, management, and industries. You can review company briefs, quickly research a new idea or opportunity, generate personalized industry reports, or set up alerts on reasons to call. Be sure to view our sample reports below.
